Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

References

• Korn S, Hübner M, Hamelmann E, Buhl R. The German severe asthma registry. Pneumologie. 2012;66(6):341–344.
   PubMedGoogle Scholar
• FitzGerald JM, Tran TN, Alacqua M, et al. International severe asthma registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020;20(1):212. doi:10.1186/s12874-020-01065-0
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2022. Available from: http://www.ginasthma.org. Accessed July 19, 2022.
   Google Scholar
• Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4):2000151. doi:10.1183/13993003.00151-2020
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Busby J, Pfeffer PE, et al. Characterisation of patients with severe asthma in the UK severe asthma registry in the biologic era. Thorax. 2021;76(3):220–227. doi:10.1136/thoraxjnl-2020-215168
   PubMed Web of Science ®Google Scholar
• Albers FC, Licskai C, Chanez P, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159:105806. doi:10.1016/j.rmed.2019.105806
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Massolo A, Bonavia M, et al. The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. Allergy. 2020;75(6):1460–1463. doi:10.1111/all.14135
   PubMed Web of Science ®Google Scholar
• Milger K, Korn S, Buhl R, et al. Age- and sex-dependent differences in patients with severe asthma included in the German asthma net cohort. Respir Med. 2020;162:105858. doi:10.1016/j.rmed.2019.105858
   PubMed Web of Science ®Google Scholar
• European Medicine Agency (EMA). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nucala. Accessed July 19, 2022.
   Google Scholar
• Miyokawa R, Kivler C, Louie S, et al. Self-administered mepolizumab in the management of severe asthma: usability and patient acceptance. Patient Prefer Adherence. 2020;14:1669–1682.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143:1742–1751.e1747.
   PubMed Web of Science ®Google Scholar
• Richards LB, van Bragt JJMH, Aarab R, et al. Treatment eligibility of real-life mepolizumab-treated severe asthma patients. J Allergy Clin Immunol Pract. 2020;8(9):2999–3008.e1. doi:10.1016/j.jaip.2020.04.029
   PubMed Web of Science ®Google Scholar
• Harvey ES, Langton D, Katelaris C, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5):1902420. doi:10.1183/13993003.02420-2019
   PubMed Web of Science ®Google Scholar
• Llanos JP, Ortega H, Bogart M, et al. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy. 2020;29(13):77–87. doi:10.2147/JAA.S236609
   Google Scholar
• Ortega H, Hahn B, Bogart M, et al. Impact of mepolizumab on exacerbations in severe asthma: results from a U.S. insurance claims data base. Allergy Asthma Proc. 2020;41(5):341–347. doi:10.2500/aap.2020.41.200043
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Pelaia G, et al. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy. 2020;50(7):780–788. doi:10.1111/cea.13613
   PubMed Web of Science ®Google Scholar
• Renner A, Marth K, Patocka K, et al. Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data. Pulm Pharmacol Ther. 2020;64:101946. doi:10.1016/j.pupt.2020.101946
   PubMed Web of Science ®Google Scholar
• Enríquez Rodríguez AI, Valverde TH, Romero AP, et al. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study. J Asthma. 2022;59(5):1005–1011. doi:10.1080/02770903.2021.1897835
   PubMed Web of Science ®Google Scholar
• Taillé C, Chanez P, Devouassoux G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020;55(6):1902345. doi:10.1183/13993003.02345-2019
   PubMed Web of Science ®Google Scholar
• Thomas D, Harvey ES, McDonald VM, et al. Mepolizumab and oral corticosteroid stewardship: data from the Australian mepolizumab registry. J Allergy Clin Immunol Pract. 2021;9(7):2715–2724.e5. doi:10.1016/j.jaip.2021.01.028
   PubMed Web of Science ®Google Scholar
• Bulathsinhala L, Eleangovan N, Heaney LG, et al. Development of the International Severe Asthma Registry (ISAR): a modified delphi study. J Allergy Clin Immunol Pract. 2019;7(2):578–588.e2. doi:10.1016/j.jaip.2018.08.016
   PubMed Web of Science ®Google Scholar
• Heffler E, Blasi F, Latorre M, et al. The severe asthma network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7(5):1462–1468. doi:10.1016/j.jaip.2018.10.016
   PubMed Web of Science ®Google Scholar
• Graff S, Vanwynsberghe S, Brusselle G, et al. Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian severe asthma registry. Respir Res. 2020;21(1):214. doi:10.1186/s12931-020-01460-7
   PubMed Web of Science ®Google Scholar
• Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020;157(4):790–804. doi:10.1016/j.chest.2019.10.053
   PubMed Web of Science ®Google Scholar
• Canonica GW, Malvezzi L, Blasi F, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947. doi:10.1016/j.rmed.2020.105947
   PubMed Web of Science ®Google Scholar
• Senna G, Latorre M, Bugiani M, et al. Sex differences in severe asthma: results from severe asthma network in Italy-SANI. Allergy Asthma Immunol Res. 2021;13(2):219–228. doi:10.4168/aair.2021.13.2.219
   PubMed Web of Science ®Google Scholar
• Yang F, Busby J, Heaney LG, et al. Factors associated with frequent exacerbations in the UK severe asthma registry. J Allergy Clin Immunol Pract. 2021;9(7). doi:10.1016/j.jaip.2020.12.062
   Web of Science ®Google Scholar
• van Bragt JJMH, Adcock IM, Bel EHD, et al. Characteristics and treatment regimens across ERS SHARP severe asthma registries. Eur Respir J. 2020;55(1):1901163. doi:10.1183/13993003.01163-2019
   PubMed Web of Science ®Google Scholar
• Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi:10.1034/j.1399-3003.1999.14d29.x
   PubMed Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65. doi:10.1016/j.jaci.2003.09.008
   PubMed Web of Science ®Google Scholar
• Schatz M, Sorkness CA, Li JT, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. Allergy Clin Immunol. 2006;117(3):549–556. doi:10.1016/j.jaci.2006.01.011
   Google Scholar
• Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the mini asthma quality of life questionnaire. Eur Respir J. 1999;14(1):32–38. doi:10.1034/j.1399-3003.1999.14a08.x
   PubMed Web of Science ®Google Scholar
• Morobeid H, Pizarro C, Biener L, et al. Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma. ERJ Open Res. 2021;7(7):00190–2021. doi:10.1183/23120541.00190-2021
   PubMedGoogle Scholar
• Bajpai S, Marino MJ, Rank MA, et al. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: a real-world study. Int Forum Allergy Rhinol. 2021;11(8):1152–1166. doi:10.1002/alr.22774
   PubMed Web of Science ®Google Scholar
• Crimi C, Campisi R, Cacopardo G, et al. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. World Allergy Organ J. 2020;13(9):100462. doi:10.1016/j.waojou.2020.100462
   PubMed Web of Science ®Google Scholar